Press Releases

Press Releases

Mapi Pharma and Mylan Strengthen Partnership to Develop and Commercialize Once-Monthly Glatiramer Acetate Depot for Relapsing-Remitting Forms of Multiple Sclerosis

NESS ZIONA, Israel, June 15, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced an additional $20 million investment from Mylan in support of continued Phase 3 clinical study progress to bring to market in the U.S. Glatiramer Acetate (GA) Depot, a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

read more

Mapi Announces First Patient Enrolled in the Phase III Clinical Trial of GA Depot for Relapsing Multiple Sclerosis (RMS)

Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS). Glatiramer acetate, the active material of Copaxone®, or its generic forms, is the most common treatment for RMS in the US. GA Depot is a long-acting depot formulation injection of glatiramer acetate administered once every four weeks, compared with the daily or thrice weekly regimen used with Copaxone® or its generic forms…

read more

Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative solutions for neurological indications, announced today that the company will present recent advancements in its pipeline for treating MS at the leading MS conference, ECTRIMS 2019, which is being held in Stockholm, Sweden on September 11-13, 2019.

read more

Mapi Pharma to Build a New Sterile Injectable Production Plant for GA Depot in Jerusalem

Sterile injectable facility will enable the supply of commercial needs as part of the agreement with Mylan. Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has signed a long term lease agreement at the Har-Hotzvim Hi-Tech Park in Jerusalem for the establishment of a new sterile production plant for GA Depot injectable products…

read more

Mapi Pharma Receives Government of Israel Funding for the Establishment of a Finished Dosage Form Facility for the Manufacturing of GA Depot Pharmaceuticals

Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the Israeli Ministry of the Economy to build a new sterile production plant for GA Depot injectable products. The approved financing plan is for a pioneering production plant for the manufacturing of a slow release formulation of Glatiramer Acetate (GA) (Copaxone®) for treating multiple sclerosis.

read more

Mapi Pharma Ltd. Announces Closing of $10 Million Investment by Zhejiang Jingxin Pharmaceutical Co.

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co., Ltd. a publicly listed Chinese pharmaceutical company manufacturing products for neurological, cardiovascular, and digestive system indications. Jingxin is also a current shareholder of Mapi Pharma, following an initial $10 million investment in 2016.

read more

Mapi Pharma Presents Phase II Extension Results of Glatiramer Acetate Depot (GA Depot) at ECTRIMS 2018 in Berlin

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company will present two-year clinical data from its Phase II study of GA Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which will take place on October 10-12 in Berlin, Germany.

read more

First Patient Treated in Mapi Pharma’s Phase II Clinical Trial of GA Depot for Primary Progressive Multiple Sclerosis (PPMS)

Mapi Pharma Ltd announced today that the first patient has been treated with GA Depot in the company’s Phase II study for primary progressive multiple sclerosis (PPMS). Glatiramer acetate, the active material of Copaxone®, is the most common treatment for RRMS in the US. GA Depot is a long-acting depot formulation injection of glatiramer acetate administered once every four weeks rather than daily or thrice weekly as in the case of Copaxone®.

read more

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

read more

First Patient Treated in Mapi Pharma’s Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis (RRMS)

Mapi Pharma Ltd. announced today that the first patient was treated in the company’s Phase IIa study of GA Depot, in development as a treatment for relapsing remitting multiple sclerosis (RRMS).  Glatiramer Acetate is the active ingredient in Copaxone®, the most common treatment for RRMS. GA Depot is a long-acting depot formulation injection of Glatiramer Acetate given once a month rather than daily or thrice weekly as in the case of Copaxone®

read more

Mapi Pharma Granted United States Patent for Pain Relief Medication “Tapentadol”

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished dosage forms based on selected drug delivery systems, announced today that the company has been granted a United States patent for Tapentadol. Tapentadol is indicated in the US and Europe for the oral treatment of moderate-to-severe acute pain.

read more

Mapi Pharma Granted United States Patent Covering the Process for the Preparation of Fingolimod for Multiple Sclerosis

Mapi Pharma Ltd. (“Mapi” or the “Company”), a developer of high-barrier to entry and high value-added generic drugs that include complex active pharmaceutical ingredients (“APIs”), formulations and life cycle management (“LCM”) products that target large markets, announced today that it was granted a United States patent covering the process for the preparation of Fingolimod, a drug currently marketed by Novartis under the trade name Gilenya.

read more